We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

T2 Biosystems

T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedica... read more Featured Products: More products

Download Mobile App




Events

24 Feb 2024 - 28 Feb 2024
05 Mar 2024 - 07 Mar 2024

Direct-From-Blood Molecular Diagnostic Test Detects Candida Auris in Just 3-5 Hours

By LabMedica International staff writers
Posted on 21 Jul 2023
Print article
Image: The Candida Auris diagnostic test has received FDA Breakthrough Device Designation (Photo courtesy of T2 Biosystems)
Image: The Candida Auris diagnostic test has received FDA Breakthrough Device Designation (Photo courtesy of T2 Biosystems)

Candida auris (C. auris) is a fungal pathogen resistant to multiple drugs and is recognized as a significant worldwide health risk due to its high mortality rate of up to 60%. Its identification is challenging with conventional lab techniques, often leading to improper treatment. To reduce the burden of this fungal disease, public health officials are being urged to continue promoting the crucial benefits of early detection and appropriate treatment. Now, a direct-from-blood molecular diagnostic test can detect C. auris directly from blood in just 3-5 hours, eliminating the need to wait for several days for a positive blood culture.

T2 Biosystems’ (Lexington, MA, USA) C. auris direct-from-blood molecular diagnostic test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA). This is the third product from T2 Biosystems to receive FDA Breakthrough Device designation after the company's T2Resistance Panel and T2Lyme Panel previously received the same designation. The company intends to expand its FDA-approved T2Dx Instrument's test options by including the C. auris diagnostic test, designed to detect C. auris directly from the blood within 3-5 hours, thus eliminating the days-long wait for a positive blood culture.

Currently, T2 Biosystems markets and sells the T2Candida Panel, the only FDA-approved diagnostic test capable of detecting sepsis-causing fungal pathogens directly from blood, thereby eliminating the need to wait for days for a positive blood culture. The T2Candida Panel, which runs on the fully automated T2Dx Instrument, can simultaneously detect five Candida species, including Candida albicans, Candida tropicalis, Candida parapsilosis, Candida krusei, and Candida glabrata. Rapid detection of these pathogens, as well as C. auris, is critical to ensuring infected patients receive suitable antifungal therapy, enhancing clinical outcomes.

"We are pleased with the FDA’s decision to grant Breakthrough Device designation for our Candida auris test, which provides greater and more frequent access to the FDA and may accelerate our path to FDA clearance,” said John Sperzel, Chairman and CEO of T2 Biosystems. “We believe adding Candida auris to the test menu on our FDA-cleared T2Dx Instrument will provide clinicians with a valuable tool to rapidly detect a dangerous, multidrug-resistant fungal pathogen much faster than blood culture-based methods, strengthening our value proposition and increasing the attractiveness of our products to U.S. hospitals.”

Related Links:
T2 Biosystems 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control

Print article

Channels

Clinical Chemistry

view channel
Image: Wireless Point-of-Care Testing for Hepatitis B Virus (Photo courtesy of Chulalongkorn University)

Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step

Hepatitis B, a significant global health concern, is responsible for chronic liver diseases like cirrhosis and liver cancer which is one of the most common cancers worldwide. The challenge with hepatitis... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Pathology

view channel
Image: The photoacoustic spectral response sensing instrument is based on low-cost laser diodes (Photo courtesy of Khan et al., doi 10.1117/1.JBO.29.1.017002)

Compact Photoacoustic Sensing Instrument Enhances Biomedical Tissue Diagnosis

The pursuit of precise and efficient diagnostic methods is a top priority in the constantly evolving field of biomedical sciences. A promising development in this area is the photoacoustic (PA) technique.... Read more

Industry

view channel
Image: The companies will develop genetic testing systems based on capillary electrophoresis sequencers (Photo courtesy of 123RF)

Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems

Sysmex Corporation (Kobe, Japan) and Hitachi High-Tech Corporation (Tokyo, Japan) have entered into a collaboration for the development of genetic testing systems using capillary electrophoresis sequencers... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.